Web TV Interview: ABL Diagnostics fait le point sur son activité We are happy to share our first webTV interview during which we have explained ABL Diagnostics activity and the development of our market. Co-founders of ABL Group: Dr Sayada & M. Boulmé talked about the original IPO via a reverse take over and they

Interest of HIV-1 Next-Generation Sequencing in a diagnosis laboratory in France The objective of this study consists in the analyse  the interest of HIV NGS sequencing, targeted , protease (PR), reverse transcriptase (RT), integrase (INT) and V3 loop or of the complete genome at the virology department of the University Hospital of Caen and the

ABL Diagnostics increases its production capacities and its resilience thanks to the “France Relance” program ABL Diagnostics is pleased to announce that a substantial increase of its molecular assays production capacities has been allowed thanks to the RESILIENCE France Relance program entitled “SOUTIEN A L’INVESTISSEMENT ET LA MODERNISATION DE L’INDUSTRIE“.  In the context of the

ABL Diagnostics signed a Channel Partner Agreement with Illumina to offer, combined with ABL Diagnostics’ DeepChek™ products, on the iSeq™ 100 and MiSeq™ next-generation sequencing platforms to microbiology laboratories in mainland France Belgium and Luxembourg ABL Diagnostics is pleased to announce a strategic collaboration with Illumina through an international Channel Partners Agreement conferring to ABL

Meet us at MEDICA 2022 Meet us at MEDICA 2022 and Discover our Microbiology Genotyping SolutionsABL will be attending the next MEDICA forum in Düsseldorf from 14 – 17 November 2022 (Luxembourg Ministry of Economy – Hall 3 / A74).  Please come by our booth. We will introduce you our 360° expertise in molecular diagnostics and genotyping by

ABL Diagnostics sponsored the NTDD Symposium in Utrecht (NL) ABL Diagnostics sponsored the NTDD Symposium in Utrecht and presented the DeepChek® kit for Tuberculosis Genotyping & Drug Resistance through NGS sequencing 🧬. Our Sales representatives Vito Grasso and Joffrey BIGNOUNGA had the opportunity to meet the very kind Dutch TB community.

Set up of New Generation Sequencing (NGS) for the detection of Ganciclovir Resistance in the Molecular Biology Laboratory of the Hospital de Clínicas. We would like to thank our local representative in Uruguay Biko which is our local representative in Uruguay and Molecular Biology Laboratory of the Hospital de Clínicas for highlighting our CMV genotyping

ABL DIAGNOSTICS, key player in the diagnosis of infectious diseases by genotyping, presents its development plan to the financial community ABL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX 2027 medium-term development plan to the financial community. Formed from the end-August 2022 merger of ABL France into the listed entity without activity ETABLISSEMENTS FAUVET-GIREL

Atout Capital a conseillé ABL Diagnostics pour la fusion-absorption de l’activité diagnostic médical d’ABL France à hauteur de 28 m€ ABL DIAGNOSTICS développe, fabrique et commercialise des kits de tests de diagnostic par détection moléculaire et de tests de génotypage par séquençage d’ADN, ciblant des maladies infectieuses chroniques. ABL DIAGNOSTICS a ainsi développé des produits

ABL Diagnostics at the Federation of Infection Societies congress Discover the scientific publications from our Innovation team and get more information about new products & services including:  Publication #1 (Poster n°98) Whole Genome Sequencing of Human BK Polyomavirus Using Next-Generation Sequencing View Descamps Veronique1,  Morel Virginie1,  Olivia Ardizzoni,   Amira Doudou,  Chalom Sayada,  Sofiane Mohamed, and Brochot